Literature DB >> 31419286

Combination of Azithromycin and Gentamicin for Efficient Treatment of Pseudomonas aeruginosa Infections.

Huan Ren1, Yiwei Liu1, Jingyi Zhou1, Yuqing Long1, Chang Liu1, Bin Xia1, Jing Shi1, Zheng Fan1, Yuying Liang2, Shuiping Chen2, Jun Xu3, Penghua Wang3, Yanhong Zhang4, Guangbo Zhu5, Huimin Liu5, Yongxin Jin1, Fang Bai1, Zhihui Cheng1, Shouguang Jin6, Weihui Wu1.   

Abstract

BACKGROUND: Trans-translation is a ribosome rescue system that plays an important role in bacterial tolerance to environmental stresses. It is absent in animals, making it a potential treatment target. However, its role in antibiotic tolerance in Pseudomonas aeruginosa remains unknown.
METHODS: The role and activity of trans-translation during antibiotic treatment were examined with a trans-translation-deficient strain and a genetically modified trans-translation component gene, respectively. In vitro assays and murine infection models were used to examine the effects of suppression of trans-translation.
RESULTS: We found that the trans-translation system plays an essential role in P. aeruginosa tolerance to azithromycin and multiple aminoglycoside antibiotics. We further demonstrated that gentamicin could suppress the azithromycin-induced activation of trans-translation. Compared with each antibiotic individually, gentamicin and azithromycin combined increased the killing efficacy against planktonic and biofilm-associated P. aeruginosa cells, including a reference strain PA14 and its isogenic carbapenem-resistance oprD mutant, the mucoid strain FRD1, and multiple clinical isolates. Furthermore, the gentamicin-azithromycin resulted in improved bacterial clearance in murine acute pneumonia, biofilm implant, and cutaneous abscess infection models.
CONCLUSIONS: Combination treatment with gentamicin and azithromycin is a promising strategy in combating P. aeruginosa infections.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  zzm321990 Pseudomonas aeruginosazzm321990 ; antibiotic combination; azithromycin; trans-translation

Mesh:

Substances:

Year:  2019        PMID: 31419286     DOI: 10.1093/infdis/jiz341

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  Pneumonia prevention in the elderly patients: the other sides.

Authors:  Najla Chebib; Clémence Cuvelier; Astrid Malézieux-Picard; Thibault Parent; Xavier Roux; Thomas Fassier; Frauke Müller; Virginie Prendki
Journal:  Aging Clin Exp Res       Date:  2019-12-31       Impact factor: 3.636

2.  Novel Lytic Phages Protect Cells and Mice against Pseudomonas aeruginosa Infection.

Authors:  Feng Chen; Xingjun Cheng; Jianbo Li; Xiefang Yuan; Xiuhua Huang; Mao Lian; Wenfang Li; Tianfang Huang; Yaliu Xie; Jie Liu; Pan Gao; Xiawei Wei; Zhenling Wang; Min Wu
Journal:  J Virol       Date:  2021-01-20       Impact factor: 5.103

Review 3.  Current State of Respiratory Syncytial Virus Disease and Management.

Authors:  Archana Chatterjee; Kunjana Mavunda; Leonard R Krilov
Journal:  Infect Dis Ther       Date:  2021-03-03

4.  Population-based serology reveals risk factors for RSV infection in children younger than 5 years.

Authors:  Stijn P Andeweg; Rutger M Schepp; Jan van de Kassteele; Liesbeth Mollema; Guy A M Berbers; Michiel van Boven
Journal:  Sci Rep       Date:  2021-04-26       Impact factor: 4.379

Review 5.  Antibiotic Combination Therapy: A Strategy to Overcome Bacterial Resistance to Aminoglycoside Antibiotics.

Authors:  Nuoyan Wang; Jing Luo; Fei Deng; Yasi Huang; Hong Zhou
Journal:  Front Pharmacol       Date:  2022-02-23       Impact factor: 5.810

6.  Isolation and characterization of two homolog phages infecting Pseudomonas aeruginosa.

Authors:  Niu Yuanyuan; Yang Xiaobo; Wang Shang; Yang Yutong; Zhou Hongrui; Li Chenyu; Xue Bin; Zhang Xi; Zhao Chen; Shen Zhiqiang; Wang Jingfeng; Ling Yun; Yu Pingfeng; Qiu Zhigang
Journal:  Front Microbiol       Date:  2022-07-14       Impact factor: 6.064

7.  Clinical Efficacy and In Vitro Drug Sensitivity Test Results of Azithromycin Combined With Other Antimicrobial Therapies in the Treatment of MDR P. aeruginosa Ventilator-Associated Pneumonia.

Authors:  Yuqin Huang; Wenguo Wang; Qiang Huang; Zhengyan Wang; Zhuanzhuan Xu; Chaochao Tu; Dongli Wan; Miaobo He; Xiaoyi Yang; Huaqiang Xu; Hanqin Wang; Ying Zhao; Mingli Tu; Quan Zhou
Journal:  Front Pharmacol       Date:  2022-08-10       Impact factor: 5.988

8.  Neutrophil-mediated delivery of the combination of colistin and azithromycin for the treatment of bacterial infection.

Authors:  Jiacong Gao; Xueyan Hu; Congjuan Xu; Mingming Guo; Shouyi Li; Fan Yang; Xiaolei Pan; Fangyu Zhou; Yongxin Jin; Fang Bai; Zhihui Cheng; Zhenzhou Wu; Shuiping Chen; Xinglu Huang; Weihui Wu
Journal:  iScience       Date:  2022-08-30

Review 9.  Variability of murine bacterial pneumonia models used to evaluate antimicrobial agents.

Authors:  Rakel Arrazuria; Bernhard Kerscher; Karen E Huber; Jennifer L Hoover; Carina Vingsbo Lundberg; Jon Ulf Hansen; Sylvie Sordello; Stephane Renard; Vincent Aranzana-Climent; Diarmaid Hughes; Philip Gribbon; Lena E Friberg; Isabelle Bekeredjian-Ding
Journal:  Front Microbiol       Date:  2022-09-08       Impact factor: 6.064

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.